Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: The VERIfy Thrombosis risk ASsessment (VERITAS) study.
Thromb Res. 2006 Mar; Malinin A, Pokov A, Spergling M, Defranco A, Schwartz K, Schwartz D, Mahmud E, Atar D, Serebruany V. |
Activation of coagulation system during air travel: a crossover study.
Lancet. 2006 Mar; 367(9513):832-8. Schreijer AJ, Cannegieter SC, Meijers JC, Middeldorp S, Buller HR, Rosendaal FR. |
Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
Am Heart J. 2006 Mar; 151(3):689-10. Greenbaum AB, Grines CL, Bittl JA, Becker RC, Kereiakes DJ, Gilchrist IC, Clegg J, Stankowski JE, Grogan DR, Harrington RA, Emanuelsson H, Weaver WD. |
A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria.
Crit Care Med. 2006 Mar; 34(3):625-31. Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, Mayumi T, Murata A, Ikeda T, Ishikura H, Ueyama M, Ogura H, Kushimoto S, Saitoh D, Endo S, Shimazaki S; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Stud |
Pharmacological characterization of 4-methoxy-N1-(4-trans-nitrooxycyclohexyl)-N3-(3-pyridinylmethyl)-1,3-benzenedicarboxamide (2NTX-99), a potential antiatherothrombotic agent with anti-thromboxane and NO-donor activity in platelet and vascular prepa
J Pharmacol Exp Ther. 2006 Feb; Epub ahead of print Dic Buccellati C, Sala A, Rossoni G, Capra V, Rovati GE, Di Gennaro A, Folco G, Colli S, Casagrande C. |
Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integr
Am Heart J. 2006 Feb; 151(2):373-9. Fitchett DH, Langer A, Armstrong PW, Tan M, Mendelsohn A, Goodman SG; INTERACT Trial Long-Term Follow-Up Investigators. |
Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.
JAMA. 2006 Ene; 295(3):306-13. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. |
Coronary artery atherosclerosis is related to reduced regional left ventricular function in individuals without history of clinical cardiovascular disease: the Multiethnic Study of Atherosclerosis.
Arterioscler Thromb Vasc Biol. 2006 Ene; 26(1):206-11. Epub 2005 Nov 3. Dic Edvardsen T, Detrano R, Rosen BD, Carr JJ, Liu K, Lai S, Shea S, Pan L, Bluemke DA, Lima JA. |
Antiplatelets in stroke prevention: the MATCH trial. Some answers, many questions and countless perspectives.
Cerebrovasc Dis. 2005 Dic; 20(Suppl 2):109-18. Bezerra DC, Bogousslavsky J. |
Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Am Heart J. 2005 Dic; 150(6):1177-84. Lewis BS, Mehta SR, Fox KA, Halon DA, Zhao F, Peters RJ, Keltai M, Budaj A, Yusuf S; CURE trial investigators. |
Cilostazol in secondary prevention of stroke: Impact of the Cilostazol Stroke Prevention Study.
Atheroscler Suppl. 2005 Dic; 6(4):33-40. Matsumoto M. |
Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study.
J Am Coll Cardiol. 2005 Nov; 46(10):1820-6. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Lancet. 2005 Nov; 366(9497):1607-21. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. |
Venous thromboembolism and mortality after hip fracture surgery: the ESCORTE study.
J Thromb Haemost. 2005 Sep; 3(9):2006-14. Rosencher N, Vielpeau C, Emmerich J, Fagnani F, Samama CM |
Effectiveness of the concomitant use of bivalirudin and drug-eluting stents (from the prospective, multicenter BivAlirudin and Drug-Eluting STents [ADEST] study).
Am J Cardiol. 2005 Sep; 96(5):659-63. Dangas G, Lasic Z, Mehran R, Cox D, Ghali MG, Henry TD, Teirstein PS, Stella JF, Browne KF Jr, Lewis SA, Knopf W, Leon MB, Moses JW, Stone GW. |
Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials.
JAMA. 2005 Ago; 294(7):819-25. Kastrati A, Dibra A, Eberle S, Mehilli J, Suarez de Lezo J, Goy JJ, Ulm K, Schomig A. |
Meta-Analysis of Trials Comparing Oral Anticoagulation and Aspirin versus Dual Antiplatelet Therapy after Coronary Stenting. Clues for the Management of Patients with an Indication for Long-Term Anticoagulation Undergoing Coronary Stenting.
Cardiology. 2005 Jul; 104(2):101-106. Rubboli A, Milandri M, Castelvetri C, Cosmi B. |
Common promoter polymorphisms of inflammation and thrombosis genes and longevity in older adults: the cardiovascular health study.
Atherosclerosis. 2005 Jul; 181(1):175-83. Epub 2005 Feb 19 Reiner AP, Diehr P, Browner WS, Humphries SE, Jenny NS, Cushman M, Tracy RP, Walston J, Lumley T, Newman AB, Kuller LH, Psaty BM |
TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study.
J Thromb Haemost. 2005 Jul; 3(7):1503-10. Morange PE, Tregouet DA, Frere C, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Cambien F, Tiret L, Juhan-Vague I; The Prime Study Group. |
Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study.
Thromb Haemost. 2005 Jul; 94(1):17-25. Wu O, Robertson L, Langhorne P, Twaddle S, Lowe GD, Clark P, Greaves M, Walker ID, Brenkel I, Regan L, Greer IA. |